Answers are grounded in this paper and cite their sources.
This commentary focuses on the exciting, unprecedented FDA accelerated approval of Tarlatamab in SCLC and highlights potential challenges that will be faced by Oncology community in integrating such I
No takes yet. Share an insight, caveat, or question.
Desai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: